Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma Non-Hodgkin Lymphoma	NCT ID:	NCT04756726
Trial Phases:	Phase I Phase II	Protocol IDs:	CFT7455-1101 (primary) NCI-2021-05587
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	C4 Therapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04756726

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with
Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
administered according to different dosing schedules as a single agent and in combination
with dexamethasone (in MM subjects only).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.